<DOC>
	<DOCNO>NCT01694472</DOCNO>
	<brief_summary>The purpose study evaluate clinical safety preliminary efficacy MAGE-A4 TCR Gene-Modified T lymphocytes treatment malignant solid tumor patient , malignant melanoma lung cancer .</brief_summary>
	<brief_title>Clinical Safety Preliminary Efficacy MAGE-A4 TCR Gene-Modified T Cells Treat Malignant Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Sex : male female Age : 18 80 year Patients must histologically confirm solid tumor fail standard therapy ( surgery , chemotherapy , radiotherapy ) curative option exist , include , limited : NonSmall Cell Lung Carcinoma Malignant melanoma Esophageal carcinoma Head neck carcinoma HLAA*24:02 MAGEA4 positive test RTPCR tumor tissue immunohistochemistry resect tissue patient . PS ECOG 0 &lt; 2 Laboratory test result 7 day start treatment : White blood cell : 3.0 × 109/L Platelets : 100 × 109/L Neutrophils : 1.5 × 109/L Hemoglobin : 80g/L Serum glutamate pyruvate transaminase : le 2.5 fold upper normal limit ( ULN ) Serum glutamicoxal ( ) acetic transaminase : le 2.5 × ULN Serum bilirubin : le 1.25 × ULN Serum creatinine : le 1.25 × ULN Pregnancy test : test woman childbearing period must negative 7 day start treatment Contraception : male female subject childbearing period must adopt reliable method contraception entry study 30 day stop study Informed consent : subject must ability understand voluntarily sign write informed consent Patients lifethreatening condition complication basic disease Pregnant lactation . Patients male female reproductive potential ( i.e . menopausal le 1 year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration Active systemic infection History neoplasm : neoplasms Medical history : active CNS disease , congestive heart failure , severe coronary artery disease , cardiac arrhythmia , concomitant corticosteroid therapy Metastasis : clinical symptom brain metastasis Other clinical trial : subject receive clinical trial study Laboratory test : serum test human immunodeficiency virus , hepatitis B virus , hepatitis C virus positive Compliance : poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>